DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has a price-to-earnings (PE) ratio of 11.4 in the Healthcare sector.

What is the market capitalisation of Gujarat Terce Laboratories Ltd?

Gujarat Terce Laboratories Ltd has a market capitalisation of approximately ₹26 crore.

Gujarat Terce Laboratories Ltd

GUJARATTERCELABORATORIESLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

High-quality returns — 31% on equity

52W₹29

₹60-94%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹26 Cr

P/E Ratio

11.40Cheap

P/B Ratio

2.59

EPS

₹-1.32

Book Value

₹12.49

ROE

30.70%Strong

ROCE

41.41%Efficient

Dividend Yield

0.00%

Debt / Equity

0.13Low

Face Value

₹10.00

52W High

₹59.78

52W Low

₹29.00

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

None moatHigh uncertainty

Fair value estimate

₹8

No recent traded price

BearFair valueBull

₹7₹8₹9

/100

Business quality — Solid

Growth 50Profitability 50Efficiency 100Valuation 95

Plain English

Our view

High-quality returns — 31% on equity
Low debt relative to equity

Strengths

Low debt relative to equity
Strong returns on equity (31%)
Capital is working hard (ROCE 41%)
Reasonably priced at 11× earnings

How we got there

Fair value methods

Residual income

-15% ROE fading to 12% over ~3 yrs, on ₹12 book

₹8

Relative P/E

Needs positive EPS

—

Graham floor

Needs positive EPS

—

Analyst target

No analyst coverage

—

Blended fair value₹8

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (31%)
Capital is working hard (ROCE 41%)
Reasonably priced at 11× earnings

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

11.4Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

30.7%Strong

Above 15% is considered healthy for Indian equities

ROCE

41.4%Efficient

Above 18% means capital is working hard

Debt/Eq

0.13Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹26 Cr

P/B

2.59

EPS

₹-1.32

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 11.4×

Growth

Slow

+0% rev CAGR

Profitability

Excellent

30.7% ROE

Financial health

Rock solid

D/E 0.13

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+0.5%

+13.5%

10Y

+6.6%

Profit

—

10Y

—

EPS

—

10Y

—

Profile

Cons

Company has a low return on equity of 7.95% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

40%

Promoter

Promoters

40.0%0.00

Public

54.4%-0.21

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

5.6%

Total shareholders

13,755+5 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter40.03%

Public54.37%

Others5.60%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics